Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below Two Hundred Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.92 and traded as low as $2.89. Cryo-Cell International shares last traded at $2.94, with a volume of 16,518 shares traded.

Cryo-Cell International Stock Performance

The stock has a 50-day moving average price of $3.34 and a two-hundred day moving average price of $3.92. The stock has a market capitalization of $23.70 million, a PE ratio of -9.48 and a beta of 0.55.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.47) earnings per share (EPS) for the quarter. The company had revenue of $7.84 million during the quarter.

Institutional Trading of Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent quarter. 10.44% of the stock is currently owned by institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.